Leo Zacharias, MD
Internal Medicine · Darby, PANPI 1346221777
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 455 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,937 and has fallen 56.6% since, to $1,274 in 2025. Among internal medicine clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 455 payments — averaging $19.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$855
- Lilly USA, LLC$850
- Boehringer Ingelheim$844
- Novo Nordisk$612
- AbbVie$611
- plus $4K from 30 others
What the payments were for
- Food & beverage$9,01999%
- Education$521%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 61 | $1,079 |
| AstraZeneca | 46 | $855 |
| Lilly USA, LLC | 43 | $850 |
| Boehringer Ingelheim | 39 | $844 |
| Novo Nordisk | 35 | $612 |
| AbbVie(2 entities) | 31 | $611 |
| Pfizer | 27 | $548 |
| Sanofi-aventis U.S. LLC | 13 | $463 |
| Merck | 19 | $427 |
| Johnson & Johnson(2 entities) | 21 | $411 |
| Astellas Pharma US Inc | 20 | $402 |
| Exact Sciences | 15 | $314 |
| Amgen | 16 | $265 |
| Novartis | 15 | $259 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $156 |
| Bayer | 5 | $127 |
| Dexcom, Inc. | 4 | $122 |
| E.r. Squibb & Sons, L.L.C. | 5 | $91 |
| Vanda Pharmaceuticals Inc. | 3 | $79 |
| Amarin Pharma, Inc. | 4 | $73 |
| Urogen Pharma, Inc. | 3 | $60 |
| 180 Medical, Inc. | 2 | $58 |
| Otsuka America Pharmaceutical, Inc. | 2 | $49 |
| Convatec Inc. | 1 | $43 |
| Abbott | 2 | $36 |
| Regeneron Healthcare Solutions, Inc. | 2 | $36 |
| BD | 1 | $34 |
| Ironwood Pharmaceuticals, Inc | 2 | $30 |
| Sunovion Pharmaceuticals Inc. | 1 | $26 |
| Verona Pharma, Inc. | 1 | $20 |
| Ardelyx, Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Shield Therapeutics Inc | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Circassia Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$224
- STEGLATRO$125
- SOLIQUA 100/33$119
- ELIQUIS$117
- MOUNJARO$108
How this compares
$9,071 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 188 | $232,566 |
| EliquisApixaban | 173 | $178,471 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 153 | $111,683 |
| TrulicityDulaglutide | 75 | $90,679 |
| JanuviaSitagliptin Phosphate | 60 | $80,259 |
| XareltoRivaroxaban | 59 | $69,697 |
| LinzessLinaclotide | 62 | $67,019 |
| EntrestoSacubitril/Valsartan | 30 | $57,683 |
| OzempicSemaglutide | 61 | $56,706 |
| RybelsusSemaglutide | 28 | $49,524 |
| MounjaroTirzepatide | 36 | $36,810 |
| FarxigaDapagliflozin Propanediol | 27 | $36,062 |
| MyrbetriqMirabegron | 52 | $33,918 |
| JanumetSitagliptin Phos/Metformin Hcl | 24 | $28,041 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 41 | $27,857 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat | $844 | $241,388205 claims |
| PfizerEliquis | $548 | $178,471173 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,079 | $155,562235 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $850 | $127,489111 claims |
| MerckJanuvia, Janumet, Janumet Xr | $427 | $115,58797 claims |
| Novo NordiskOzempic, Rybelsus | $612 | $106,23189 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $855 | $72,897103 claims |
| Johnson & JohnsonXarelto | $411 | $69,69759 claims |
| AbbVieLinzess | $611 | $67,01962 claims |
| NovartisEntresto | $259 | $57,68330 claims |
| Astellas Pharma US IncMyrbetriq | $402 | $33,91852 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $463 | $10,29612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Darby
- Abhishek BhardwajDarby$110K
- Jonathan EpsteinPhiladelphia$13.1M
- Pitamber DevgonPhiladelphia$7.5M
- Daniel RaderPhiladelphia$1.7M
- Mohammed KidwaiBala Cynwyd$894K
- Ronak BhimaniNorristown$623K
- David GoldmannPhiladelphia$525K
- Christopher StillDanville$442K
- Jeffrey FreidLower Gwynedd$425K
- Cheryl PegusSpring House$370K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.